Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer

European Journal of Cancer

Volumn 48, Issue 9, 2012, Pages 1293-1298

  Khattak, Muhammad A ^a   Townsend, Amanda R ^a   Beeke, Carol ^d   Karapetis, Christos S ^d   Luke, Colin ^b   Padbury, Rob ^d   Maddern, Guy ^a   Roder, David ^c   Price, Timothy J ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b DEPARTMENT OF HEALTH   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Chemotherapy; Colorectal; Elderly; Registry; Survival

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; AGING; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DRUG CHOICE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; SOUTH AUSTRALIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861333288     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.09.029     Document Type: Article

References (30)

1. J. Ferlay, F. Bray, and P. Pisani GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0 2004 IARC Press Lyon, France
2. A. Grothey, D. Sargent, and R.M. Goldberg Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 7 2004 1209 1214
3. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2 2004 229 237
4. A. Grothey, and D. Sargent Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line J Clin Oncol 23 36 2005 9441 9442
5. Australian Institute of Health and Welfare Chronic diseases and associated risk factors in Australia, 2001 2002 Australian Institute of Health and Welfare Canberra
6. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) 17 Registry (2000-2003): age-Adjusted Incidence Rates. Bethesda, MD: National Cancer Institute. www.seer.cancer.gov.csr.
7. V. Sundararajan, N. Mitra, and J. Jacobson Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer Ann Intern Med 136 2002 349 357
8. A. Potosky, L. Harlan, and R. Kaplan Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer J Clin Oncol 20 2002 1192 1202
9. V. Lemmens, A. van Halteren, and M. Janssen-Heijnen Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity Ann Oncol 16 2005 767 772
10. G. Folprecht, D. Cunningham, and P. Ross Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Ann Oncol 15 2004 1330 1338
11. D. Sargent, R. Goldberg, and S. Jacobson A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients N Engl J Med 345 2001 1091 1097
12. C. Köhne, G. Folprecht, and R. Goldberg Chemotherapy in elderly patients with colorectal cancer Oncologist 13 4 2008 390 402
13. T. McKibbin, C.R. Frei, and R.E. Greene Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting Oncologist 13 8 2008 876 885
14. M. Koopman, N.F. Antonini, and J. Douma Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 2007 135 142
15. M.T. Seymour, T.S. Maughan, and J.A. Ledermann Different strategies of sequential and combination chemotherapy for patients with poor-prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 2007 143 152
16. M. Alam, G. Gabriel, and M. Barton Discriminating factors in treatment decisions for chemotherapy in elderly patients with colorectal cancer CancerForum 32 1 2008
17. National Cancer Database. Commission on Cancer, ACoS. Benchmark Reports, v1.1, October 1, 2007.
18. C. Ho, K. Ng, and H. O'Reilly Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis Clin Colorectal Cancer 5 4 2005 279 282
19. P. Simmonds Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis BMJ 321 2000 531 535
20. V. Sundararajan, N. Mitra, and J.S. Jacobson Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer Ann Intern Med 136 2002 349 357
21. R.A. Popescu, A. Norman, P.J. Ross, B. Parikh, and D. Cunningham Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older J Clin Oncol 17 1999 2412 2418
22. G. Folprecht, P. Rougier, and L. Slatz Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: meta-analysis of four trials investigating 5-FU and irinotecan (abstract 3578) J Clin Oncol 24 18S 2006 165s
23. R.M. Goldberg, I. Tabah-Fisch, and H. Bleiberg Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer J Clin Oncol 24 2006 4085 4091
24. J. Cassidy, L.B. Saltz, and B.J. Giantonio Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies J Cancer Res Clin Oncol 136 2010 737 743
25. N.C. Tebbutt, K. Wilson, and V.J. Gebski Capecitabine, bevacizumab and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX study J Clin Oncol 28 19 2009 3191 3198
26. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 20 2007 2040 2048
27. K. Jain, C. Beeke, and T.J. Price A population-based study of metastatic colorectal cancer (mCRC) in people age 80 and older: findings from the South Australian Clinical Registry (SACR) for mCRC J Clin Oncol 29 2011 (suppl. 4; abstr. 514)
28. L.F. Hutchins, J.M. Unger, J.J. Crowley, C.A. Coltman, and K.S. Albain Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 1999 2061 2067
29. J.H. Lewis, M.L. Kilgore, and D.P. Goldman Participation of patients 65 years of age or older in cancer clinical trials J Clin Oncol 21 2003 1383 1389
30. R.R. Jennens, G.G. Giles, and R.M. Fox Increasing underrepresentation of elderly patients with advanced colorectal or non-smallcell lung cancer in chemotherapy trials Intern Med J 36 2006 216 220